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Introduction
The term sarcopenia, indicating the age-related loss of
muscle mass, was first introduced by Dr. I.H. Rosenberg (1).
This loss of muscle mass with aging is hypothesized to have
negative consequences for health and physical functioning in
old age (2). To investigate the prevalence of sarcopenia and its
impact on health and functioning in old age, and to diagnose
sarcopenia in clinical practice, a definition should be available.
Several definitions have been developed and described in the
literature. The usefullness of these definitions is generally
tested by investigating the association between sarcopenia and
(change in) physical functioning. It is important to realize that
most of these definitions include a cutpoint for low muscle
mass, not loss of muscle mass. Currently, there is no consensus
on the definition of sarcopenia. In this brief review several
proposed definitions of sarcopenia will be described and
potential advantages and disavantages will be discussed. 
Definitions of sarcopenia
Baumgartner and collegues were the first to develop a
definition of sarcopenia (3). Based on studies showing that the
amount of appendicular skeletal muscle mass (ASMM) could
be estimated by using the bone-free, fat-free mass of the arms
and legs as assessed with whole body dual-photon
absorptiometry or dual-energy x-ray absorptiometry (DXA, 4,
5), the definition was created using ASMM. Furthermore,
analogous to the body mass index, the ASMM was devided by
height squared to adjust for the strong association between
body height and ASMM. To define the cutpoints for low
ASMM an approach similar to that of osteoporosis was taken.
Older persons with a ASMM less than two standard deviations
from the mean of a young reference population were considered
sarcopenic. DXA data from a young (aged 18-40 years)
volunteer sample of 229 non-Hispanic white men and women
participating in the Rosetta Stone study (6) were used to
determine the sarcopenia cutpoints. The developed cutpoints
were 7.26 kg/m2 for men and 5.45 kg/m2 for women (3).
Although these cutpoints are limited by the fact that the young
reference group was a volunteer sample and might not have
been representative for young US men and women (it was
actually the first young sample with available DXA
measurements) they are widely being used in sarcopenia
research. Using the same approach, sarcopenia cutpoints have
recently been developed for Asian persons (7). 
The Baumgartner cutpoints for sarcopenia were first applied
to the New Mexico Elder Health Survey in which ASMM was
predicted using an equation including sex, body weight, body
height, hip circumference and grip strength (3). After
adjustment for age, income, ethnicity, obesity, comorbidity,
current smoking,  physical activity and alcohol intake,
sarcopenic men and women were more likely to have 3
physical disabilities. In men, but not in women, sarcopenia was
also associated with >1 balance abnormality, the use of a cane
or walker, and falling in the past year.
A second definition of sarcopenia was developed by Janssen
and collegues (8). Whole body skeletal muscle mass was
estimated using a prediction equation including impedance and
reactance as assessed with bioelectrical impedance, body height
squared, sex and age. The predicted amount of muscle mass
was than expressed as the percentage of total body weight to
adjust for stature and the mass of nonskeletal muscle tissues
(fat, organ, bone). Again, analogous to the osteroporosis
definition, an index less than two standard deviations from the
sex-specific mean value of a young reference group was
considered to indicate class II sarcopenia. An index within one
to two standard deviations from the young reference group was
considered class I sarcopenia. Bioelectrical impedance data
from a nationally representative sample of young adults (aged
18-39 years) participating in the Third National Health and
Nutrition Examination Survey (NHANES III) were used to
develop the cutpoints. A potential disadvantage of the used
index is that the ratio of whole body skeletal muscle mass
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devided by total body weight is largely dependent on the
amount of body fat since the between-person variation in total
body fat is much larger compared to the between-person
variation in skeletal muscle.
In the same cross-sectional study (8), class II sarcopenia
based on the skeletal muscle index was associated with
functional impairment and disability in men and women.
However, after adjustment for age, race, body mass index,
health behaviors, and comorbidity some of the associations
disappeared. Of the 12 items, class II sarcopenia in men was
only related to the tandem stand performance and self-reported
limitations stooping/crouching/kneeling. In women, class II
sarcopenia was associated with five items.  
A third approach to define sarcopenia is the use of receiver
operating characteristic curves when examining the association
of different skeletal muscle cutpoints with physical disability in
older persons (9). Data from 4,449 men and women aged 60
years and older who participated in the NHANES III were used.
Whole body skeletal muscle mass was predicted using
bioelectrical impedance measurements and divided by height
squared. A skeletal muscle mass  5.75 kg/m2 indicated high
disability risk and a skeletal muscle mass between 5.76-6.75
kg/m2 indicated a moderate disability risk in women. The
corresponding values in men were 8.50 kg/m2 and 8.51-10.75
kg/m2. After adjustment for age, race, smoking status, alcohol
intake, comorbidity and body fat, class II sarcopenic men and
women showed a three to five-fold risk of having disability. In
men, class I sarcopenia also showed an increased risk. 
These developed cutpoints have recently been applied to
another large cohort study of older persons (Cardiovascular
Health Study) in which whole body skeletal muscle mass was
predicted based on bioelectrical impedance measurements (10).
The association of sarcopenia with disability at baseline and
with incident disability during an 8 year follow-up were
investigated. The prospective associations were generally
weaker compared to the baseline associations. With adjustment
for a large set of baseline variables and incident cardiovascular
disease, class I sarcopenia was not associated with incident
disability. Class II sarcopenia was associated with incident
disability in women (Odds ratio 1.37 (95% confidence interval
1.10-1.72) versus those with normal muscle mass) but not in
men.
Although DXA scanners have become widely available,
effort has been made in examining the use of anthropometric
measurements to define sarcopenia. The main advantage of this
approach is the greater feasability in clinical practice. In 1,458
French women aged 70 years and older the calf circumference
was most strongly associated with predicted ASMM (r=0.63).
However, a calf circumference value below 31 cm was not a
good screening tool to detect sarcopenia based on the
Baumgartner definition (sensitivity 44.3%, specificity 91.4%)
(11). 
In 2003, an alternative method was proposed to potentially
derive sarcopenia cutpoints (12). Based on the finding in the
Health, Aging and Body Composition Study that the prevalence
of sarcopenia using the original Baumgartner sarcopenia
cutpoints was very high in normal weight older persons (>50%)
but zero in obese older persons, a method was developed that
incorporated both body height and total body fat. The lowest
20th percentile of the residuals of the regression of total body
height and body fat on ASMM derived in the older men and
women separately was used to define sarcopenia. The
percentile cutpoint was chosen arbitrarily. This new definition
was compared with the lowest 20th percentile of the ratio of
ASMM divided by height squared (7.23 kg/m2 in men, 5.67
kg/m2 in women). These cutpoints turned out to be very similar
to the original Baumgartner cutpoints (3). In men, sarcopenia
according to both definitions increased the risk of having a low
function. The risk of a low function score almost doubled in
women with sarcopenia based on the residuals. In contrast,
women with sarcopenia based on the ratio had a lower risk for
having a low function. Probably, when using this definition the
non-sarcopenic group includes obese women who have a low
function score because of their excess body fat. 
The association between sarcopenia using both these
definitions and 5-year change in physical function was also
examined in the Health Aging and Body Composition Study
(13). Again, sarcopenia based on the residual method was better
for predicting incident lower-extremity mobility limitations
compared to the ratio ASMM/height2 method. In fact, men and
women with sarcopenia based on the ratio method had a lower
risk of developing incident mobility limitations which was
attenuated after adjustement for total body fat. 
Recently, an international working group was established to
work on a definition for sarcopenia. Different definitions for
sarcopenia were applied to several large aging cohorts that
include accurate, repeated measurements of ASMM by DXA
(Women Health Initiative, MrOs, Health Aging and Body
Composition Study, and the Longitudinal Aging Study
Amsterdam). New cutpoints following the Baumgartner
approach and using DXA data from young participants from the
NHANES IV study were developed and applied. Moreover,
previously established cutpoints were investigated. Preliminary
data recently presented at several scientifc meetings suggest
that sarcopenia definitions based on the ratio of ASMM and
height squared are of limited value to predict future decline in
mobility function in older persons (unpublished). 
Thus far, most of the developed definitions of sarcopenia are
based on a cutpoint for low total body skeletal muscle mass or
appendicular skeletal muscle mass. Several researchers have
started to include measures of muscle quality to determine
sarcopenia. For example, Lauretani et al. (14) investigated knee
extension isometric torque, handgrip, lower extremity muscle
power, and calf muscle area in relationship to poor mobility in
the InCHIANTI study. Sarcopenia cutpoints were developed in
the participants aged 20-29 years. Persons were considered
sarcopenic when their values were less than 2 SD of the mean
of the young reference group. Lower extremity muscle power
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was no better than knee-extension torque or handgrip in the
early identification of poor mobility. In a second set of
analyses, optimal sarcopenia cutpoints were developed using
receiver operating characteristic (ROC) curves. The areas under
de curve for handgrip, knee-extension torque, and lower
extremity muscle power were similar and not statistically
different. The area under the curve for calf muscle area was
substantially smaller. These cross-sectional results could
suggest that poor muscle strength should be preferred above
low muscle mass to assess sarcopenia. This is supported by the
findings of other epidemiological studies showing that muscle
strength measures in older persons are more strongly associated
with (change in) functional limitations and disability (15-18)
and mortality (19-20) compared to muscle mass measures.
Other studies have examined cutpoints for poor muscle
strength. In a recent study (21) cutpoints for low knee extensor
strength were developed in relationship to incident mobility
limitations. Data on 2,784 men and women aged 70-79 years,
participants of the Health, Aging and Body Composition Study
were used. Cutpoints of the ratio of knee extensor strength
(Nm) divided by body weight were 1.13 Nm/kg and 1.71
Nm/kg for high and low risk of incident severe mobility
limitations in men, and 1.01 Nm/kg and 1.34 Nm/kg in women.
Apart from the higher risk of incident mobility limitations,
persons in the high risk group also turned out to have a higher
risk for incident low gait speed (<1.22 m/sec) and 7-year
mortality. An earlier cross-sectional study in 192 older men and
women proposed a knee extensor strength cutpoint of 2.5
Nm/kg.m(-1) in relationship to functional performance tests
(22). A cutpoint of 0.80 Nm/kg.m(-1) has also been proposed
(23). A point where low leg strength starts to impair gait speed
cannot be easily identified since gait speed is influenced by
other performance factors as well (24). Finally, a potential
disadvantage for a clinical application of these proposed
cutpoints is the use of an isokinetic strength measurement.
It has been questioned whether muscle strength should also
be used to assess sarcopenia, since it implies that muscle mass
and muscle strength are causally linked while it is now known
that changes in muscle mass are not fully responsible for
changes in muscle strength. Perhaps a different terminology for
the loss of muscle strength or low muscle strength should be
used. Recently, the term dynapenia was proposed to indicate
the age-related loss of muscle strength (25).
Epidemiologic studies have shown that body fat in older
persons, and especially in older women, is often a more
important determinant of (deline in) physical function
compared to muscle mass (16, 26-29). Moreover, in some
studies the association of body fat with physical function is
even stronger than the association of muscle strength (16, 30).
The presence of high body fat as well as low muscle mass is
called sarcopenic obesity. Recently, different definitions of
sarcopenic obesity using muscle mass or muscle strength to
indicate sarcopenia have been proposed and have been shown
to be associated with incident disability (31, 32).
In conclusion, sarcopenia definitions based on the ratio of
ASMM and height squared should be interpreted carefully
because the important role of body fat is not incorporated.
Moreover, although cross-sectionally associated with physical
function, only weak or even inverse associations have been
observed with future decline in physical function. Apart from
low muscle mass, a sarcopenia definition should at least
incorporate body height and body fat since they both are
important determinants of the amount of muscle mass. For
functional outcomes a definition based on muscle strength
seems more relevant. However, it cannot be excluded that
sarcopenia definitions based on low muscle mass might be
relevant change in other health outcomes, such as glucose
homeastasis. Furthermore, thus far no studies have investigated
whether loss of muscle mass is an important determinant of
functional decline, although a definition based on change in
muscle mass would be less clinically useful. The concept
‘sarcopenic obesity’ deserves more attention in future studies,
as well as the role of other muscle quality aspects, such as fat
infiltration into the muscle.
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